Clinical Trials on Serous Carcinoma

Total 109292 results

National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Emory University
Synta Pharmaceuticals Corp.

Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditions

United States
Hospital Sirio-Libanes

Completed

Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma (THBC-HSL2)

Hepatitis | Hepatocellular Carcinomas

Brazil
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
CanariaBio Inc.
Raptim Research Pvt. Ltd

Recruiting

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Fallopian Tube Neoplasms | Ovarian Cancer | Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma | Ovarian Neoplasm Epithelial

India
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States
Xoft, Inc.
Icad, Inc.

Withdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Ductal Carcinoma In Situ | Invasive Ductal Carcinoma
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
Duke University
National Cancer Institute (NCI)

Completed

Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)

Ductal Carcinoma in Situ

United States
Indiana University
GlaxoSmithKline

Terminated

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Ductal Carcinoma in Situ

United States
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
University of Florida
Monteris Medical

Terminated

LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH)

Melanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
Chandrikha Chandrasekhara
TerSera Therapeutics LLC

Withdrawn

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS)

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (SCIROCCO)

Neuroendocrine Tumors | Carcinoid Syndrome
University of Southern California
AstraZeneca

Terminated

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Breast Carcinoma

United States
National Cancer Institute, Naples

Recruiting

Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22)

Low-grade Serous Ovarian Carcinoma | Recurrent Invasive Borderline Serous Ovarian Cancer

Italy
Casey Cosgrove

Recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recurrent Endometrial Serous Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Breast Ductal Carcinoma In Situ

United States
Sunnybrook Health Sciences Centre

Active, not recruiting

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma

Canada
Rijnstate Hospital

Terminated

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy (NAC-PNP)

Carcinoma, Non-Small-Cell Lung | Mesothelioma | Carcinoma, Small Cell Lung

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Transitional Cell Carcinoma | Metastatic Urothelial Carcinoma | Unresectable Transitional Cell Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
University of Texas at Austin
Washington University School of Medicine; Ohio State University

Completed

Living Well After Breast Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
National Cancer Institute (NCI)
Exelixis

Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditions

United States
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
Xoft, Inc.
Icad, Inc.

Active, not recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma

United States, Portugal, Australia
Roswell Park Cancer Institute

Recruiting

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast Carcinoma | Breast Ductal Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaborators

Recruiting

The PROMISE Study: Duavee in Women With DCIS

Postmenopausal | Ductal Breast Carcinoma In Situ

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Active, not recruiting

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

Ductal Breast Carcinoma In Situ

United States
Ontario Clinical Oncology Group (OCOG)

Recruiting

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) (ELISA)

DCIS

Canada
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Washington... and other collaborators

Active, not recruiting

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET)

Ductal Carcinoma in Situ | DCIS

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Breast Cancer

United States
Hologic, Inc.
University of Southern California

Completed

MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)

DCIS

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Suspended

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Unresectable Fibrolamellar...

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian Undifferentiated...

United States
Katherine D. Crew

Completed

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

Breast Neoplasms | Stage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Stage III Breast Carcinoma

United States
University of California, San Diego

Completed

Pilot Study of PDL to Treat BCC and SCCIS (PDLNMSC)

Basal Cell Carcinoma | Squamous Cell Carcinoma in Situ
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Sue O'Dorisio

Completed

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors (GA-68)

Neuroendocrine Tumors | Medulloblastoma | Neuroblastoma | Carcinoid Tumors

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Cianna Medical, Inc.

Terminated

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China

Nasopharyngeal Cancinoma (NPC)

China

Clinical Trials on Serous Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations